Imugene (ASX:IMU) reported two more complete responses in its phase 1b trial of azer-cel cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma, according to a Friday Australian bourse filing.
Four out of seven patients in the group have achieved a complete response following treatment with azer-cel, chemotherapy, as well as a low dose of interleukin 2, a protein that affects what happens between cells in the immune system, the filing added.
Azer-cel is a chimeric antigen receptor T-cell therapy, which targets CD19 to treat blood cancers.
Imugene said that it remains focused on continuing enrollment in the group, as well as evaluating the long-term durability of responses.
The firm's shares rose 8% in recent trading on Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。